Our company takes part in the 28th International exhibition of the pharmaceutical industry CPhI Worldwide 2017, which will be held Frankfurt am Main from 24th to 26 th of October. Our colleges can be seen at the booth of Qi-Chem Company as representatives of our Joint venture.
The launch of new production on the basis of the technology developed by P&M-Invest is one of the main activities of our company.Within the framework of an establishment of Joint Venture between the Chinese company Qi-Chem and P&M-Invest at the present time there is Pentafluorophenol's technology development by the representatives of the company Qi-Chem the subsequent production of this product at factory in China. Learning new technologies developed by P&M-Invest is going on at the experimental site near Moscow.
Pentafluorophenol is the main starting material for the production of the drug Sofosbuvir, which is widely used for the treatment of hepatitis C worldwide. Due to the fact that the market consumption of this product is growing rapidly, the need for medical drug is large.
Negotiations, held on February 14-17 between Qi-Chem and P&M-Invest, had resulted in the signing of an agreement to establish a joint venture.
The registration of joint venture is scheduled for April, 2017.
P&M-Invest offers “products from stock” as free samples (not more then 3 substances) in the quantity 5-20g, subject to the publication of their results, obtained based on each sample, in our journal “Fluorine notes” within 6 months. The promotion is valid within 2017.
Note: The delivery of free of samples is paid by receiver.